You just read:

Cell Therapeutics Begins Enrollment in Phase 3 PERSIST-1 Trial of Pacritinib for the Treatment of Myelofibrosis

News provided by

Cell Therapeutics, Inc.

Jan 09, 2013, 01:30 EST